 |
市场调查报告书
商品编码
1672804
全球胆管癌市场按治疗类型、通路和地区划分Bile Duct Cancer Market, By Treatment Type , By Distribution Channel, By Geography |
||||||
2025 年全球胆管癌市场规模估计为 40.3 亿美元，预计到 2032 年将达到 71.8 亿美元，2025 年至 2032 年的复合年增长率为 8.6%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025 年市场规模 | 40.3亿美元 |
| 效能资料 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年复合年增长率： | 8.60% | 2032 年价值预测 | 71.8亿美元 |
胆管癌，也称为胆道癌，是一种在胆管中发生的罕见癌症。胆管是连接肝臟和胆囊与小肠的管道。当胆管内壁细胞变得异常且不受控制地生长形成肿瘤时，就会发生胆管癌。导致胆管癌的主要危险因子包括原发性硬化性胆管炎 (PSC)、发炎性肠道疾病、肝功能不全和某些胆管先天性异常。症状包括黄疸、搔痒、腹痛、体重减轻和大便苍白。诊断通常涉及超音波、 电脑断层扫描或MRI扫描等影像检查以及切片检查。治疗方案取决于癌症的阶段，可能包括手术、放射线治疗、化疗和标靶治疗。但由于胆管癌早期发现困难且肿瘤生长缓慢，存活率较低、预后较差。
市场动态：
全球胆管癌市场的成长主要受到原发性胆管癌 (PSC) 和肝吸虫感染等风险因素日益流行的推动。根据美国疾病管制与预防中心 (CDC) 的数据，PSC 影响了美国约 3 万人。对胆管癌缺乏了解和延迟诊断也导致其在晚期才被诊断出来，从而推动了市场的成长。此外，增加标靶药物的研发资金以改善胆管癌的治疗效果也可能为市场相关人员提供有利可图的机会。然而，疾病意识低下和手术程序复杂可能会阻碍市场成长。
本研究的主要特点
- 本报告对全球胆管癌市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和復合年增长率。
- 它还揭示了各个领域的潜在商机并说明了该市场的引人注目的投资提案矩阵。
- 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
- 它根据公司亮点、产品系列、关键亮点、绩效和策略等参数，介绍了全球胆管癌市场的主要企业概况。
- 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球胆管癌市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员将透过用于分析全球胆管癌市场的各种策略矩阵更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 驱动程式
- 限制因素
- 机会
- 影响分析
- 市场趋势
- 主要进展
- 监管情景
- 收购和合作场景
- 资金筹措和投资
- PEST分析
- 波特的分析
第 4 章。全球胆管癌市场：COVID-19 大流行的影响
- 整体影响
- 政府倡议
- COVID-19 市场影响
第 5 章 全球胆管癌市场按治疗类型划分（2020-2032 年）
- 化疗
- 标靶治疗
- 免疫疗法
- 其他的
6. 全球胆管癌市场依通路划分（2020-2032 年）
- 院内药房
- 零售药局
- 网路药局
7. 全球胆管癌市场按地区划分（2020-2032 年）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- 公司简介
- F. Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck &Co., Inc.
- Novartis AG
- Celgene Corporation
- Johnson &Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Fresenius Kabi AG
- Mylan NV
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation
第九章分析师建议
- 命运之轮
- 分析师观点
- Coherent Opportunity Map（COM）
第十章参考文献与调查方法
- 参考
- 调查方法
Global Bile Duct Cancer Market is estimated to be valued at USD 4.03 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.03 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.60% | 2032 Value Projection: | USD 7.18 Bn |
Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct is a tube that connects the liver and gallbladder to the small intestine. Bile duct cancer occurs when the cells that line the bile ducts become abnormal and grow uncontrollably, forming a tumor. Key risk factors for developing bile duct cancer include primary sclerosing cholangitis (PSC), an inflammatory bowel disease, liver flukes, and certain congenital abnormalities of the bile ducts. Symptoms may include jaundice, itching, abdominal pain, weight loss, and pale stools. Diagnosis usually involves imaging tests such as ultrasound, CT scan, and MRI scans, as well as biopsy. Treatment options depend on the stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted therapy. However, bile duct cancer has a poor prognosis with low survival rates due to difficulties in early detection and slow growth nature of the tumors.
Market Dynamics:
Global bile duct cancer market growth is primarily driven by increasing prevalence of risk factors such as PSC and liver flukes infections. According to the Center for Disease Control and Prevention (CDC), PSC affects around 30,000 people in the U.S. Insufficient understanding and delays in diagnosing bile duct cancer also contribute to late-stage diagnosis, thus, driving the market growth. Moreover, rising research funding towards targeted drug development for improving the bile duct cancer treatment outcomes can offer lucrative opportunities for market players. However, low disease awareness and complexity in surgical procedures can hamper the market growth.
Key Features of the Study:
- This report provides in-depth analysis of the global bile duct cancer market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bile duct cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eli Lilly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, and Bristol-Myers Squibb Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market
Detailed Segmentation-
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- (Pembrolizumab (Phase 3))
Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Celgene Corporation
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Fresenius Kabi AG
- Mylan N.V.
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Bile Duct Cancer Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Bile Duct Cancer Market, By Treatment Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- (Pembrolizumab (Phase 3)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Bile Duct Cancer Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Bile Duct Cancer Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Celgene Corporation
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fresenius Kabi AG
- Mylan N.V.
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation
- F. Hoffmann-La Roche Ltd
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
